



The Influence of Ethnicity on Warfarin Dosage Requirements in the Chilean Population



Valeska Subiabre, MsCs^{1,2}, Ivan Palomo, PhD^{1,*}, Neftalí Guzmán, PhD^{2,6},
Eduardo Retamales, MsCs³, Hugo Henríquez, MsCs⁴, Luis Gonzalez, MsCs⁵

¹ The Clinical and Immunohematological Department, Faculty of Health Sciences, Universidad de Talca, Talca, Chile

² Molecular Diagnosis Laboratory, Faculty of Health Sciences, Universidad San Sebastián, Concepcion, Chile

³ Biomedical Laboratory Department, The National Hematology Reference Laboratory, Chile's Public Health Institute, Santiago, Chile

⁴ Escuela de Tecnología Médica, Universidad Mayor, Santiago, Chile

⁵ Internal Medicine Department, Universidad de La Frontera, Temuco, Chile

⁶ Escuela de Ciencias de la Salud, Universidad Católica de Temuco, Temuco, Chile

ARTICLE INFO

Article history:

Accepted 29 December 2014

Key words:

anticoagulant therapy
mitochondrial DNA
pharmacogenomics
warfarin

ABSTRACT

Background: Vitamin K antagonists are drugs that are widely prescribed around the world and their use has helped improve the prognosis of patients with thromboembolic disease. However, a high interindividual variability has been observed in dosage requirements to reach the desired anticoagulation range that could be due to environmental and genetic factors. Studies suggest that ethnicity influences coumarin response, supporting the observed differences in dose requirements across various populations. Studies using mitochondrial DNA (mtDNA) markers have suggested that the Chilean population has a predominantly Amerindian genetic pool.

Objective: To evaluate the influence of ethnicity, defined by the presence of Amerindian mtDNA haplogroups, on the variability in therapeutic response to warfarin in the Chilean population.

Methods: A total of 191 patients treated with warfarin were included in this study. Analysis of the mitochondrial genome for detecting the presence of Amerindian mtDNA haplogroups was performed using polymerase chain reaction and polymerase chain reaction restriction fragment length polymorphism techniques. The evaluation of warfarin requirements according to each haplogroup was performed by ANOVA with a 95% CI and assuming statistical significance at $P < 0.05$.

Results: Based on the presence of an mtDNA haplogroup, 91% of the Chilean population had an Amerindian background. There were no significant differences in warfarin dosage requirements among the different Amerindian haplogroups ($P = 0.083$).

Conclusions: The presence of Amerindian mtDNA haplogroup does not influence warfarin dosage requirements in the Chilean population.

© 2015. The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Anticoagulant therapy has improved the prognosis of patients with a variety of conditions, including prevention and/or treatment of venous thrombosis, pulmonary embolism, and thromboembolic complications associated with atrial fibrillation and mechanical prosthetic heart valves. However, there is wide interindividual variability in dose requirements to achieve the desired anticoagulation range. A variety of both genetic and environmental factors contribute to this phenomenon. These include body

weight; age; vitamin K intake; drug interactions; allelic variants in cytochrome P450 2C9 and vitamin K epoxide reductase complex, subunit 1 (VKORC1); and ethnicity. Several studies have shown the influence of cytochrome P450 2C9 and VKORC1 variability in dosage requirements, explaining a significant proportion of variation in drug response.¹ In Latin American populations, there is little evidence regarding the frequency of occurrence of the polymorphisms and variability in the response to oral anticoagulant therapy. Guzman et al² provide some background in the Chilean population when they describe the frequency of variant VKORC1 1639 G > A, associating with lower requirements of warfarin, but this association was not observed for genotype CYP2C9*2. In addition, factors such as age and body weight independently influence dose requirements. Furthermore, several

* Address correspondence to: Iván Palomo, XX, The Clinical and Immunohematological Department, Universidad de Talca, Talca 3460000 Chile.

E-mail address: ipalomo@utalca.cl (I. Palomo).

Table 1
Clinical and demographic characteristics of Chilean patients treated with warfarin.

Characteristic	Men (n = 77)	Women (n = 114)
Age, y*	65 (13.0)	66 (13.4)
Height, m*	1.70 (0.0)	1.56 (0.0)
Weight, kg*	79.6 (15.3)	68 (14.2)
Hypertension†	47 (61)	66 (57.9)
Diabetes mellitus†	11 (14.2)	10 (8.7)
Dyslipidemia†	12 (15.5)	26 (22.8)

* Values are given as mean (SD).

† Values are given as n (%).

studies suggest that ethnicity is an important factor that may influence the dosage requirements of the antagonists of vitamin K. A clear example of this is the lower requirements of coumarin in Asian patients (between 30% and 40%) compared with white populations,³ a factor that could influence dose requirements of antagonists of vitamin K.⁴ Because of the value that has been given to ethnicity as a factor that might influence dosage requirements of coumarin, mitochondrial DNA (mtDNA) is an appropriate tool to assess this variable, given its unique features. It has a high rate of variation in sequence (5–10 times greater than that in nuclear DNA) and it behaves as haploid gene inheritance via maternal parent over generations and not does not undergo genetic recombination. Its sequence has been completely known since 1981; it comprises 16,569 base pairs in 37 gene segments. The mtDNA noncoding is concentrated in the area called loop D, with approximately 1,100 base pairs, which shows a high degree of polymorphism in sequence.^{5,6}

Available scientific evidence suggests that ethnicity is a determining factor in oral anticoagulant dosage requirements.⁷ For example, Asian populations show requirements between 30% and 40% lower than white populations, whereas African populations require significantly higher dosages than white populations.⁸

Studies on population genetics show that the Chilean population has a mainly Amerindian genetic background, determined by using mitochondrial genome markers named Amerindian mtDNA haplogroups.⁹ Interestingly, in a recent study conducted on patients treated with atorvastatin, a high frequency of Amerindian mtDNA haplogroups was described, showing that haplogroup B individuals had higher levels of total cholesterol after treatment,¹⁰ suggesting that the presence of this mitochondrial genome marker may define a lower response to treatment using this lipid-lowering drug.

According to the evidence that shows the mainly Amerindian component of the Chilean population and the absence of evidence that shows the influence of ethnicity on warfarin response in the Amerindian population, the aim of our study was to evaluate the potential association between the presence of Amerindian mtDNA haplogroups and the variability in warfarin dosage requirements.

Materials and Methods

Population under study

A total of 191 patients older than age 18 years (77 men with a mean [SD] age of 65 [13] years and 114 women with a mean [SD] age of 66 [13] years) and being treated at 2 medical centers in the cities of Santiago and Temuco, Chile, were included in the study. The group was patients receiving oral anticoagulant treatment using warfarin with a low international normalized ratio (between 2 and 3) in at least the previous 2 medical checks. Patients younger than age 18 years and patients with chronic liver disease were excluded from the study.

All patients included in the study signed an informed consent form, in accordance with the basic criteria for biomedical research listed in the Declaration of Helsinki. After signing the informed consent form, each patient was surveyed to gather relevant clinical epidemiologic information for the study, as well as to measure anthropometric parameters such as weight and size to calculate body mass index.

Amerindian mtDNA haplogroup characterization

Venous blood anticoagulated with EDTA was extracted using standard methods and the genomic DNA was extracted using whole blood using the standardized methodology described by Salazar et al.¹¹

The Amerindian mtDNA haplogroup characterization was conducted in accordance with the method described.¹² Amplification reactions were carried out in a final volume of 25 μ L with 50 ng genomic DNA, 100 mM of each primer, 200 mM of each of the 4 deoxyribonucleotides, 1 unit of Taq DNA polymerase, and polymerase chain reaction buffer (50 mM potassium chloride, 2 mM magnesium chloride, 20 mM ammonium sulfate, and 75 mM Tris-hydrogen chloride; pH 9.0). To determine presence or absence of the 3 polymorphic restriction sites typical in the haplogroups A, C, and D of the Amerindian population, digestion with specific endonucleases *Hae III*, *Hinc II*, and *Alu I*, respectively, was conducted.

Finally, the restriction fragments were evaluated by electrophoresis in 3% agarose gel stained with GelRed (Biotium Inc, Hayward, California). Regarding the marker that defines the B haplogroup and consists of deleting 1 of the 2 9-base pair repetitions located in the V intergenic region, visualization was conducted by electrophoresis in 3% agarose gel directly from the polymerase chain reaction products obtained. All the gels were analyzed by 2 people and 20% of the analyses were randomly repeated for internal control measures.

Statistical Analysis

Amerindian mtDNA haplogroup frequencies were estimated/calculated directly. To evaluate the differences in warfarin dosage requirements considering the presence of an Amerindian mtDNA haplogroup, an ANOVA test was conducted, with a 95% CI and considering a statistical significance value of $P < 0.05$.

Results

Clinical and demographic characteristics of the patients included in this study are shown in **Table 1**. The mean age of the patients evaluated was similar between men and women, at 66 years and 65 years, respectively. Also it should be noted that of the

Table 2
Amerindian mitochondrial DNA haplogroup frequency in patients treated with warfarin.

Haplogroup	Patient	
	n	%
A	14	7.3
B	60	31.4
C	56	29.3
D	44	23.1
NA	17	8.9
Total	191	100

NA = Not Amerindian.

Download English Version:

<https://daneshyari.com/en/article/4196797>

Download Persian Version:

<https://daneshyari.com/article/4196797>

[Daneshyari.com](https://daneshyari.com)